Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 July 2023 | Story Andre Damons | Photo Samkelo Fetile
Prof Catherine Comiskey
Prof Catherine Comiskey, a professor in Healthcare Statistics from the School of Nursing and Midwifery at Trinity College Dublin and Academic Director of CHARM-EU, presents a lecture on building a research career with global impact to members of the UFS Transformation of the Professoriate Mentoring Programme.

A visiting scholar from Trinity College Dublin in Ireland visited the University of the Free State (UFS) to work with staff members from the UFS Transformation of the Professoriate Mentoring Programme on identifying collaborations, writing, and building a research career.

Prof Catherine Comiskey, a professor in Healthcare Statistics from the School of Nursing and Midwifery at Trinity College Dublin and Academic Director of CHARM-EU – an EU-funded academic programme – held a writing retreat for participants in the Transformation of the Professoriate Mentoring Programme in the last week of June. She also worked with individual members to identify potential European and UK collaborators on various research projects. On Friday 30 June, she presented a lecture on building a research career with global impact.

Encouraging staff members

According to Dr Henriëtte van den Berg, Manager: Transformation of the Professoriate Mentoring Programme, Prof Comiskey encouraged colleagues to develop a research and publication strategy to ensure that they optimise the work they are doing, to look for opportunities to collaborate with colleagues across different disciplines, and to work together on publications and the supervision of postgraduate students.

“She also emphasised the importance of collaborating with people in industry, as they often have a rich source of data that is publishable. She highlighted the importance of being an ethical researcher. The workshop participants benefited from her passion and broad knowledge to start planning collaborations and to reflect on how they can make the work they are already doing work more for them. A group of workshop participants has already started working on a systematic review that they will conduct in collaboration with Prof Comiskey,” said Dr Van den Berg.

Share expertise

Prof Comiskey facilitated online writing interventions for the colleagues of the mentoring programme during COVID-19 lockdown restrictions. She was invited to the campus to share her expertise in quantitative methodology and transdisciplinary work.

Prof Comiskey completed a PhD in Mathematics and coordinates many interdisciplinary research teams, comprising applied mathematicians, statisticians, psychologists, medical doctors, sociologists, anthropologists, nurses, computer scientists, and healthcare employees. She has been selected as one of five international experts nominated by the European Commission to serve on the International Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction.

She has 30 years’ experience of teaching, research, postgraduate supervision, and teaching to specialists and non-specialists in all areas of applied statistics, mathematics, and epidemiology. She is also a seasoned academic leader, having served as Research Director at Trinity College, Dublin for many years.

CHARM-EU is an EU-funded academic programme spanning five European universities to develop, run, and evaluate a new EU-wide model for Universities of the Future. This involves a new transdisciplinary master’s degree that addresses the Sustainable Development Goals (SDG).  

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept